First Tracks Biotherapeutics (MEX:TRAX) 3-1 Month Momentum %: N/A% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:TRAX First Tracks Biotherapeutics Inc MEX:TRAX
12 GF Score
Price MXN800.00
! 2 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics 3-1 Month Momentum %?

First Tracks Biotherapeutics MEX:TRAX 12 3-1 Month Momentum % is N/A% as of Aug. 27, 2026. GuruFocus rates MEX:TRAX with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 1,384 Biotechnology companies, First Tracks Biotherapeutics ranks better than 98.84% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), First Tracks Biotherapeutics's 3-1 Month Momentum % is N/A%.

The industry rank for First Tracks Biotherapeutics's 3-1 Month Momentum % or its related term are showing as below:

MEX:TRAX's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: -9.34
* Ranked among companies with meaningful 3-1 Month Momentum % only.

First Tracks Biotherapeutics  (MEX:TRAX) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

First Tracks Biotherapeutics 3-1 Month Momentum % Related Terms

MEX:TRAX
12GF Score
First Tracks Biotherapeutics Inc MEX:TRAX
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics  (MEX:TRAX) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of N/A% mean?
First Tracks Biotherapeutics (MEX:TRAX) has a 3-1 Month Momentum % of N/A% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #16 out of 1384 companies in the Biotechnology industry, placing it in the top 1.2%.
Is First Tracks Biotherapeutics' 3-1 Month Momentum % too high?
First Tracks Biotherapeutics' current 3-1 Month Momentum % is N/A%. Based on the distribution chart, First Tracks Biotherapeutics ranks #16 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' 3-1 Month Momentum % compare to AVLN and IMTX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #16 out of 1384 companies for 3-1 Month Momentum %. This places First Tracks Biotherapeutics in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (MEX:TRAX) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For First Tracks Biotherapeutics (MEX:TRAX), the current 3-1 Month Momentum % is N/A% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USAB43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for MEX:TRAX

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN800.00
Price